Grateful to @MROQC1's efforts to deliver high quality radiation to michiganders! Bone met RT in 5 or fewer fractions: 📈 Is increasing & quality measure launch is independently associated. 🏥 Is good for system resources 🚙 Is patient-centered 🏞️ Is environmentally friendly

From #RedJournal: @MROQC1 shows substantial variation in intended ADT use across a statewide consortium for men w/ intermed. risk prostate cancer and show a lack of consensus w/ the benefits and harms of ADT in this patient population. @mdsquared44 bit.ly/reddess1

Wonderful farewell dinner for our graduating residents. Extremely bittersweet to see (most of) you fly the coop but you’ll always be part of the @UMichRadOnc family. It’s been such a joy to work with you all, but it’s time for you to show the world what you got! @MichRadOncRes

As a field, we've spent millions figuring out the role of ADT with RT for INT risk prostate cancer, but in this project we found that providers still lack consensus about ADT prescription in real world practice. Work in @IJROBP with @MROQC1 @SamReganMD @rtdess

🚨🚨RTOG 0848🚨🚨 Anatomically resectable PDAC randomized postoperatively 1st randomization: Gemcitabine /- erlotinib 🔥2nd Randomization🔥 /- Chemoradiation, 50.4 Gy/28 fx cape ✅⬆️ DFS w/ ☢️ ✅N0, ⬆️DFS and OS (5y 48% vs 29%) w/ ☢️ #ASCO24 @NRGonc

Amazing experience to be part of the #YouthSummit at the Big House. So great to see the future leaders of healthcare! @UMichRadOnc @umichmedicine

Seriously though, a PHYSICS ⚛ CURRICULUM is finally here! @VarianMedSys & ARRO bring you this peer-reviewed resource, full of modules and ways to test yourself! Register ⬇now for access just in time for @ABR_Radiology physics boards on June 25! bit.ly/3wkV562

ORATOR2 primary analysis from @drdavidpalma @ESTRO_RT #ESTRO24 (60 Gy cis if 7th ed N2 vs essentially 3311 treatment) - RT with improved OS (and PFS)!

So excited and grateful to be a part of this team and collaboration!

Very grateful for the opportunity to present at @btfoundation cancer health disparities conference! In collaboration with @CancerRayos, we showed that longitudinal lectures significantly improved contouring knowledge compared to written resources alone.

What I learned in 🇨🇱 today … $5mill = one #radiotherapy machine☢️, can treat 10k patients. $5mill = 135 patients worth of trastuzumab. 🧐 @TheLancetOncol - tinyurl.com/6bry9a2a “an essential pillar in multi-D oncology…an inexpensive modality” - 👏🏽 well said @TargetingCancer

This is what pains me about focal and the GU field and even organizations that standby silent: We learn to maximize benefit and minimize harm through carefully conducted controlled trials. 99% of these tx are done off trial. Most RCTs are negative bc we are wrong often even when ph2 promising. Focal phase 2 trials largely disappointing. Even ignoring that there is a >50% chance these tx harm more than help, but doctors are literally willing to take these pts cash and harm countless men. This is bc: If focal was truly better they are harming millions of men by not answering the question carefully in a trial to change SOC and provide it to all… And if focal is worse they are harming millions of men indefinitely by pretending it helps, bankrupting families, and causing irreversible harm. There are places that have focal tumor boards and the institutions enable it. There is no good data to support using it, let alone pretend you have any clue who it is good for. It’s like having a focal brachy tumor board = anecdotes leading anecdotes. The decay of EBM. Embarrassment for doctors to do off trial, disgrace the field stands by silent while these men are being harmed. If focal is so amazing do the dang RCT to SBRT and mandate it be on trial. Otherwise just admit you happily take cash from patients for a treatment that may ultimately be worse for them than SOC and you have no good data to prove otherwise. Many professions take ppls money. Sad this is rampant in GU.

What an amazing day here at @MichRadOncRes welcome to our new residents! Can’t wait for 2025! 💙💛 #goblue

Congrats to resident @SamReganMD on his talk at #HNCS24 on a phase 2 trial of FDG-PET based approach to selective de-escalation of chemoRT in early stage HPV oropharynx cancer! @UMichRadOnc

Please check out our new article in Lancet Oncology - The Radiation Planning Assistant: addressing the global gap in radiotherapy services @MDAndersonNews thelancet.com/journals/lanon…

First time advocating with my congressional representative's office (@RepDebDingell) as part of the UMich Residents and Fellows for Global Health Equity. We're asking for federal funding to support global health residency training. Let me know if you're interested in joining!

A radiation oncologist at @UMichMedicine discussed a recent publication that explores how nucleotides can affect brain cancer's sensitivity or resistance to chemotherapy and radiation, potentially leading to breakthroughs in cancer treatment. myumi.ch/byk89

Congrats to two of our residents, Michael Dykstra and Sam Regan, for winning Conquer Cancer Merit Awards for their ASCO GU symposium abstracts! Both will be presenting work done with @MROQC1. conquer.org/news/conquer-can… @mdsquared44 @SamReganMD @UMichRadOnc @UMichMedSchool

🚨 EXTEND Ph 2 pancreatic ca ≤ 5 metastases 1:1 R to MDT plus systemic therapy versus systemic therapy alone mPFS 10.3 versus 2.5 months p=0.006 HR 0.43 (95% CI 0.20, 0.94; p=0.03) Nice work! H/T @ebludmir meetings.asco.org/2024-asco-…

HAIL! The Michigan Wolverines are NATIONAL CHAMPIONS! 🏆 #GoBlue